Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.
All News
Article
David Liew
Tweet
@benjaminsutu @RheumNow Always steroids first, we learned that the hard way in GUSTO - but yeah, probably something after that, and TCZ is our only b/tsDMARD choice... for the time being
(at #ACR21 - mavrilimumab, baricitinib, secukinumab...)
Janet Pope
Tweet
Blurred line btwn RA, preRA & RA prevention which makes interpretation of RCTs problematic. I’ve learned that if pt has RA not meeting criteria, some Rx ⬇️chance of RA over time-MTX, now #Abatacept but was it RA anyway AND what happens when you stop Rx? #ACR21 @RheumNow abst#0505 https://t.co/HwivsITvCQ
#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine:
RA vs AAV/IIM
Higher IgG
Longer time-to-RTX
Lower RTX courses Number.
Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz
Role of anti-CK antibodies:
👉⬆️susceptibility to severe mycobacterial dz & opportunistic infx (similar to HIV)
👉causes an indeterminate quantiferon (no response to mitogen)
👉initiated by infx➡️anti-Noc2 Ab➡️cross react with IFN➡️IFN-Ab
👉⬆️severity of #COVID19 #ACR21 1/2 https://t.co/5NHQpwQw6X
#GreatDebate: add belimumab (BLMB) vs. voclosporin (VCS) to MMF for lupus nephritis (LN)
Dr. Petri argues for BLMB b/c: (1/2)
👉improvement in LN
👉improvement in non-renal lupus
👉decrease lupus renal mortality
👉**prevent GFR reduction **
👉long term efficacy
#ACR21 @rheumnow
Donald Thomas, MD
Tweet
#ACR2021 Dr. L Sammaritano shows evidence for using belimumab during breastfeeding @RheumNow https://t.co/kDXXauoOZQ
IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers?
⬆️IL-22 in AxSpA vs. controls
⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP
Abs#385
#ACR21
@RheumNow https://t.co/hNtStAluJH
Dr. Antoni Chan
Tweet
Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
Dr. Antoni Chan
Tweet
Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE
Janet Pope
Tweet
#ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
Retrospective study of FAERS database: 186 irAE w/rheum manifestation
👉4.7% of all AEs
👉Arthritis, myositis, Sjogren, sarcoidosis were frequent
👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
David Liew
Tweet
How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination?
Better chance of response if:
- RA or SLE, not AAV or IIM
- high serum IgG pre-last RTX
- longer time since last RTX
Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ treated patients. Interesting concept that needs to be replicated in larger trials. Abs 0193 #ACR21 #RheumNow @RheumNow https://t.co/awqOpwg3gH https://t.co/lGzYglnkyM
Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2
David Liew
Tweet
How much ritux for AAV maintenance?
Ever since we started using it, no-one's been sure.
If absolute B cell depletion is your goal, @VUMCRheum data suggest >3.3mg/d is safest for that
500mg q6m = 2.7 mg/d
500mg q4m = 4.1 mg/d
1000mg q6m = 5.5mg/d
#ACR21 ABST0416 @RheumNow https://t.co/mYAgKhHT7j
Richard Conway
Tweet
Dr Springer on pharmacological response of RTX in ANCA-vasculitis. Suggest that 500mg every 6 months may not achieve sufficient B cell depletion in all. What are the clinical implications? Is anyone dosing 500mg as standard? Abstr#0416 #ACR21 @RheumNow https://t.co/w36hSYbW1B
David Liew
Tweet
Despite >20y of bDMARDs, our patients still have a 50% greater risk of cardiovascular issues
(similar to family history or abdominal obesity)
Cardiovascular disease in RA is not historic, it's today's reality we too often ignore.
2020 data @VUamsterdam #ACR21 ABST0286 @RheumNow https://t.co/Az4wHNUOGe
David Liew
Tweet
PsA bDMARD use in Australia🇦🇺
(where once you qualify for a bDMARD in general, it's the physician's free choice)
1. cool Sankey diagram showing switches
2. given the chance, people switch in all directions & switch hard
(registry linked with insurance)
#ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
